| Database ID | Agent | Target | Cancer Type | Detail |
| DB00886 | everolimus | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00887 | sunitinib | FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | advanced solid tumors | view |
| DB00888 | temsirolimus | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00889 | PKC412 | mRNA of MCL1 | non small cell lung cancer | view |
| DB00890 | lapatinib | Epidermal growth factor receptor
Receptor proteintyrosine kinase erbB2 | breast cancer | view |
| DB00891 | imatinib, bevacizumab, and metronomic cyclophosphamide | NA | colorectal cancer | view |
| DB00892 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | liver cancer | view |
| DB00893 | brivanib | vascularendothelial growth factor and fibroblast growth factor receptors | liver cancer | view |
| DB00894 | brivanib | vascularendothelial growth factor and fibroblast growth factor receptors | liver cancer | view |
| DB00895 | gefitinib erlotinib | NA | non small cell lung cancer | view |
| DB00896 | erlotinib | Epidermal growth factor receptor | breast cancer | view |
| DB00897 | AG013736 | Macrophage colonystimulating factor 1
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | advanced solid tumors | view |
| DB00898 | panitumumab | Epidermal growth factor receptor | biliary tract and gallbladder cancer | view |
| DB00899 | bevacizumab, erlotinib | NA | colorectal cancer | view |
| DB00900 | everolimus and temozolomide | NA | pancreatic cancer | view |